OBJECTIVES:  A novel passive ventricular restraint is the non-transplant surgical option for the management of end-stage dilated heart failure (HF). The objective of this work is to expand the therapeutic techniques of current medicine, for this purpose, we design a novel ventricle restraint device (ASD) which has the ability to deliver a therapeutic drug directly to the heart. In this study, we deliver a Traditional Chinese Medicine (TCM) Salvia Miltiorrhiza (Danshen Zhusheye, SM) through active hydraulic ventricles support drug delivery system (ASD) and we hypothesize that it will have a better result in heart failure management than the restraint device and drug alone. METHODS: Sprague-Dawley (SD) rats were selected and divided into five groups (n=6), Normal, HF, HF+SM (IV), HF+ASD, HF+ASD+SM groups respectively. Prior to surgery, ECG was performed which showed a normal heart function in all groups. RESULTS:  The HF+ASD-SM group showed a significant therapeutic improvement with respect to other treatment groups. Masson-Trichrome staining was used to study histopathology of cardiac myocytes, a large blue fibrotic area was observed in HF, HF+ASD, and HF+SM (IV) groups while HF+ASD+SM showed negligible fibrotic myocytes on histological examination at the end of study period (30 days). The diastolic and systolic parameter (LVEDP and LVSP) were brought to normal when treated with HF+ASD+SM and show significant (P value< 0.05) over individual ASD and SM therapy. Blood Brain Natriuretic Peptide (BNP) significantly as declines in HF+ASD+SM group animals compared with HF and HF+SM (IV) groups respectively. CONCLUSIONS:  It is concluded that novel ASD device augments the therapeutic effect of a drug and can deliver Salvia miltiorrhiza to the cardiomyocytes significantlyas well as provide additional support to the dilated ventricle by the result of heart failure.